{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:23:15Z","timestamp":1793013795926,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In 2023, 2 forms of respiratory syncytial virus (RSV) prevention, maternal RSV vaccine and nirsevimab, became available for infants. The factors that played a role in their uptake during the first 2 seasons remain unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe the rate of RSV immunization through maternal RSV vaccination or nirsevimab during the 2023-2024 and 2024-2025 RSV seasons and identify the factors associated with their receipt.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was performed at clinical sites affiliated with a quaternary care hospital in New York, New York, from October 1, 2023, to March 31, 2024, and October 1, 2024, to March 31, 2025. Participants included infants younger than 8 months who had at least 1 clinical encounter during the 2023-2024 and 2024-2025 RSV seasons.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were receipt of RSV immunization by maternal RSV vaccine 14 days or more prior to delivery or nirsevimab. No evidence of RSV immunization was defined as either no documentation of either product or receipt of maternal vaccine less than 14 days prior to delivery without subsequent nirsevimab immunization. A multinomial logistic regression model was used to estimate odds ratios (ORs) controlling for age, sex, RSV season, insurance, and race and ethnicity, to assess factors associated with vaccination.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 13\u202f195 eligible infants (6831 [51.8%] male; 8367 [63.4%] newborn; median age of nonnewborn infants, 17.7 [IQR, 8.1-26.9] weeks), 11\u202f804 of 12\u202f913 (91.4%) were born at term (gestational age \u226537 weeks), 11\u202f208 of 12 964 (86.5%) were privately insured, and 12\u202f109 of 13 195 (91.8%) were born at the study institution. A total of 8830 infants (66.9%) received RSV immunization through maternal RSV vaccine (3832 [29.0%]) or nirsevimab (4998 [37.9%]). RSV immunization coverage increased from 3595 of 6245 infants (57.6%; maternal RSV vaccine, 1317 [21.1%]; nirsevimab, 2278 [36.5%]) in the 2023-2024 season to 5235 of 6950 (75.3%; maternal RSV vaccine, 2515 [36.2%]; nirsevimab, 2720 [39.1%]) in the 2024-2025 season. Increased odds of receiving maternal RSV vaccine (adjusted OR [AOR], 3.58; 95% CI, 3.22-3.99) and nirsevimab (AOR, 1.89; 95% CI, 1.73-2.06) were associated with the 2024-2025 season compared with the 2023-2024 season. Lower odds of receiving maternal RSV vaccine (AOR, 0.18; 95% CI, 0.15-0.22) or nirsevimab (AOR, 0.80; 95% CI, 0.70-0.89) were associated with public compared with private insurance.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of eligible infants younger than 8 months, receipt of RSV immunization through maternal RSV vaccine or nirsevimab improved in the 2024-2025 compared with the 2023-2024 RSV seasons. However, infants with public insurance were less likely to receive either product, highlighting persistent disparities in RSV immunization warranting targeted interventions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.59663","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:30:25Z","timestamp":1771259425000},"page":"e2559663","source":"Crossref","is-referenced-by-count":6,"title":["Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab"],"prefix":"10.1001","volume":"9","author":[{"given":"Karen P.","family":"Acker","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Strobino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"DeAngelis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Staniczenko","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeun","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Riley","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika L.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York"},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary M.","family":"Grinspan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York"},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"zoi251585r1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-065623","article-title":"Respiratory syncytial virus\u2013associated hospitalizations in children <5 years: 2016-2022.","volume":"154","author":"McMorrow","year":"2024","journal-title":"Pediatrics"},{"issue":"10340","key":"zoi251585r2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"zoi251585r3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus\u2013associated mortality in young children (RSV GOLD): a retrospective case series.","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"41","key":"zoi251585r4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus\u2013associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"zoi251585r5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"zoi251585r6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi251585r7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants.","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi251585r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60735","article-title":"Respiratory syncytial virus vaccine and nirsevimab uptake among pregnant people and their neonates.","volume":"8","author":"Blauvelt","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi251585r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60729","article-title":"Maternal RSVpreF and infant nirsevimab immunizations uptake during respiratory syncytial virus season.","volume":"8","author":"Litman","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251585r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.53696","article-title":"Uptake of maternal RSV vaccination and infant nirsevimab among infants born October 2023 to March 2024.","volume":"8","author":"Jacobson","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi251585r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes.","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi251585r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.20440","article-title":"Nirsevimab uptake in a pediatric primary care network during the 2023-2024 RSV season.","volume":"8","author":"Schaffer DeRoo","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi251585r14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-070790","article-title":"Disparities in nirsevimab uptake across a pediatric primary care network.","volume":"156","author":"Ahmed","year":"2025","journal-title":"Pediatrics"},{"issue":"5","key":"zoi251585r15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/pediatric17050109","article-title":"Sociodemographic factors, intent-uptake disparities, and nirsevimab availability in infant RSV immunoprophylaxis.","volume":"17","author":"Lipsett","year":"2025","journal-title":"Pediatr Rep"},{"issue":"5","key":"zoi251585r16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.acap.2018.02.010","article-title":"Development and validation of the pediatric medical complexity algorithm (PMCA) version 3.0.","volume":"18","author":"Simon","year":"2018","journal-title":"Acad Pediatr"},{"issue":"31","key":"zoi251585r17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"Respiratory syncytial virus immunization coverage among infants through receipt of nirsevimab monoclonal antibody or maternal vaccination\u2014United States, October 2023-March 2024.","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi251585r19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/diseases11010023","article-title":"Racial disparities and common respiratory infectious diseases in children of the United States: a systematic review and meta-analysis.","volume":"11","author":"Jones","year":"2023","journal-title":"Diseases"},{"issue":"11","key":"zoi251585r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34147","article-title":"Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis.","volume":"4","author":"Magesh","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"38","key":"zoi251585r21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.15585\/mmwr.mm7338a3","article-title":"Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021\u2014National Immunization Survey-Child, United States, 2021-2023.","volume":"73","author":"Hill","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi251585r23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1870","article-title":"Elimination of perinatal hepatitis B: providing the first vaccine dose within 24 hours of birth.","volume":"140","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"zoi251585r24","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.amepre.2019.05.005","article-title":"Hepatitis B birth dose: first shot at timely early childhood vaccination.","volume":"57","author":"Oster","year":"2019","journal-title":"Am J Prev Med"},{"issue":"38","key":"zoi251585r25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.15585\/mmwr.mm7338a2","article-title":"Maternal respiratory syncytial virus vaccination and receipt of respiratory syncytial virus antibody (nirsevimab) by infants aged <8 months\u2014United States, April 2024.","volume":"73","author":"Razzaghi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi251585r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedcp.2025.200160","article-title":"Physician practices, attitudes, and challenges related to pediatric COVID-19 vaccination in the United States.","volume":"17","author":"Kang","year":"2025","journal-title":"J Pediatr Clin Pract"},{"issue":"9","key":"zoi251585r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0331326","article-title":"Nurses\u2019 attitudes about RSV vaccination for pregnant women and infants: evidence from a cross-sectional survey.","volume":"20","author":"Viskupic","year":"2025","journal-title":"PLoS One"},{"key":"zoi251585r8","unstructured":"Limited availability of nirsevimab in the United States\u2014recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023-2024 respiratory virus season. US Centers for Disease Control and Prevention. October 23, 2023. Accessed May 4, 2025. https:\/\/www.cdc.gov\/han\/2023\/han00499.html"},{"key":"zoi251585r18","unstructured":"Sanofi Beyfortus (nirsevimab-alip) statement. Sanofi US News. Updated October 26, 2023. Accessed November 15, 2025. https:\/\/www.news.sanofi.us\/Sanofi-Beyfortus-Statement"},{"key":"zoi251585r22","unstructured":"RSV immunization guidance for infants and young children. US Centers for Disease Control and Prevention. August 30, 2024. Accessed May 4, 2025. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/infants-young-children.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2845127\/acker_2026_oi_251585_1772733800.94203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:00:28Z","timestamp":1772737228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2845127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.59663","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}